No credit card. No commitment.
5000+ G2 reviews
Belite Bio
Research
Public company
Founded in 2018
San Diego, CaliforniaBelite Bio
ResearchPublic companyFounded in 2018San Diego, California
EmployeesBelite Bio's financial review
Employees
18
Total Funding
36M
Last Funding Round
36M
nasdaq
BLTE
Market cap
974.5M
Belite Bio information
Belite Bio (NASDAQ: BLTE) is a San Diego based clinical stage drug development company targeting untreatable eye diseases, such as dry AMD and Stargardt disease (STGD1) which is the most common inherited retinal dystrophy, and metabolic diseases. Its lead pipeline, Tinlarebant (aka LBS-008), is a novel oral once-a-day tablet intended to treat Dry AMD and STGD1 early. Tinlarebant is in phase 3 and ...
Belite Bio (NASDAQ: BLTE) is a San Diego based clinical stage drug development company targeting untreatable eye diseases, such as dry AMD and Stargardt disease (STGD1) which is the most common inherited retinal dystrophy, and metabolic diseases. Its lead pipeline, Tinlarebant (aka LBS-008), is a novel oral once-a-day tablet intended to treat Dry AMD and STGD1 early. Tinlarebant is in phase 3 and has been granted Fast Track & RPD designation in the US, and ODD in the US and EMA for STGD1.
Belite Bio industries
Rbp4
Drug development
Dry agerelated macular degeneration
Stargardt disease
Belite Bio's financial review
Employees
18
Total Funding
36M
Last Funding Round
36M
nasdaq
BLTE
Market cap
974.5M
Employee Metrics
Technologies
Fonts
Other
Web Performance Monitoring
Tag Management
Fonts
Captcha
Employees
Prospect on LinkedIn
Find verified emails and direct dial mobile numbers of contacts on LinkedIn, and sync them with your CRM instantly
Download Extension
Why our clients choose Apollo
“Apollo completely changed the game for us. It allowed us to identify relevant targets that are ready to scale and reach out to them at the exact right time.”
Erik Straub
Head of Product, Kickfurther
“Using Apollo.io, we've solved the biggest problem for every business, the lead problem. We are now constrained by sales time and no longer lack interested prospects.”
Michael Transon
CEO, Victorious
